Cibc World Market Inc. Has $181.83 Million Position in Eli Lilly and Company $LLY

Cibc World Market Inc. grew its stake in Eli Lilly and Company (NYSE:LLY) by 26.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 238,314 shares of the company’s stock after acquiring an additional 49,634 shares during the quarter. Cibc World Market Inc.’s holdings in Eli Lilly and Company were worth $181,833,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Dash Acquisitions Inc. raised its holdings in Eli Lilly and Company by 2.8% in the second quarter. Dash Acquisitions Inc. now owns 485 shares of the company’s stock worth $387,000 after purchasing an additional 13 shares during the period. Nvest Financial LLC grew its holdings in shares of Eli Lilly and Company by 0.6% in the 2nd quarter. Nvest Financial LLC now owns 2,274 shares of the company’s stock valued at $1,773,000 after buying an additional 13 shares during the period. MPS Loria Financial Planners LLC increased its position in shares of Eli Lilly and Company by 1.9% in the 2nd quarter. MPS Loria Financial Planners LLC now owns 699 shares of the company’s stock valued at $545,000 after buying an additional 13 shares in the last quarter. Key Client Fiduciary Advisors LLC raised its stake in Eli Lilly and Company by 1.2% during the 3rd quarter. Key Client Fiduciary Advisors LLC now owns 1,136 shares of the company’s stock worth $867,000 after buying an additional 13 shares during the period. Finally, Darwin Wealth Management LLC raised its stake in Eli Lilly and Company by 3.6% during the 3rd quarter. Darwin Wealth Management LLC now owns 373 shares of the company’s stock worth $285,000 after buying an additional 13 shares during the period. Institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 31st. UBS Group reiterated a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 2nd. Truist Financial set a $1,281.00 target price on shares of Eli Lilly and Company in a report on Thursday, February 5th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Eli Lilly and Company from $1,200.00 to $1,285.00 and gave the company a “buy” rating in a research note on Monday. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Eli Lilly and Company in a report on Monday, December 22nd. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,217.71.

Eli Lilly and Company Price Performance

NYSE LLY opened at $1,025.06 on Wednesday. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The company has a market capitalization of $969.08 billion, a PE ratio of 44.66, a price-to-earnings-growth ratio of 0.90 and a beta of 0.39. The firm’s 50 day moving average is $1,051.59 and its 200-day moving average is $902.97.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping the consensus estimate of $7.48 by $0.06. The business had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 112.50%. The firm’s revenue was up 42.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 30.15%.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly agreed to acquire Orna Therapeutics for up to $2.4 billion to add in vivo CAR‑T and circular RNA capabilities — a long‑term bet to broaden genetic‑medicine and cell‑therapy exposure. Lilly to acquire Orna Therapeutics to advance cell therapies
• Positive Sentiment: Lilly moved eloralintide (LY3841136) into Phase 3 for obesity, extending its leadership in weight‑loss therapeutics and potential longer‑term revenue streams beyond current GLP‑1s. Lilly Advances Eloralintide Into Phase 3, Expanding Its Obesity Drug Ambitions
• Positive Sentiment: Solbinsiran advanced in a Phase 2 study targeting high‑risk cholesterol patients, strengthening Lilly’s cardiovascular pipeline outside diabetes/obesity. Eli Lilly’s Solbinsiran Trial Advances in High-Risk Cholesterol Market
• Positive Sentiment: Strong 2025 results and 2026 guidance underpin optimism: Lilly reported large revenue and EPS growth driven by GLP‑1 sales, and analysts forecast continued double‑digit revenue and earnings expansion next year. Eli Lilly’s 2025 Surge Sets the Stage for Another Big Year in 2026
• Neutral Sentiment: Lilly expanded a large strategic collaboration with Innovent Biologics (multi‑billion potential), increasing global oncology/immunology reach but with milestone‑contingent upside. Eli Lilly Enters $8.5 Billion Strategic Collaboration with Innovent Biologics and Acquires Orna Therapeutics
• Neutral Sentiment: Deutsche Bank raised its price target on LLY, signaling continued analyst confidence, but lofty targets may already reflect much of the upside. Benzinga
• Negative Sentiment: Revenue concentration risk: over 60% of recent sales still come from GLP‑1 drugs (Mounjaro, Zepbound), leaving the stock sensitive to competitive dynamics, pricing and policy risk. Over 60% of Eli Lilly’s Revenue Comes From Its GLP-1 Drugs. Should Investors Be Worried?
• Negative Sentiment: Some shareholders trimmed positions (e.g., Bristol Gate Capital), and after the recent triple‑digit run, profit‑taking and rotation into other names likely pressure the share price in the near term. Bristol Gate Capital Partners Trims Eli Lilly Stake

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.